No profile data available.
Adicet Bio, Inc. (ACET) is a healthcare company in the autoimmune treatment pharmaceuticals industry, based in Boston, United States, with about 102 full-time employees.
In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its largest business segment, Human Health, brought in 49% of segment revenue in fiscal year 2017; UNITED STATES was the largest region with 76%. Its market capitalization was $52.52 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States.
Human Health, with $315.40 million or 49% of segment revenue in fiscal year 2017. Next: Performance Chemicals (26%) and Pharmaceutical Ingredients (25%).
UNITED STATES: 76% of revenue by region in fiscal year 2017, followed by GERMANY (12%).
$52.52 million as of October 9, 2026.
Listed companies of a similar size in the same industry (autoimmune treatment pharmaceuticals) include Cue Biopharma, Inc. (CUE), Nkarta, Inc. (NKTX), Immunic, Inc. (IMUX), Kezar Life Sciences, Inc. (KZR).